



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/13957/2012

European Medicines Agency decision P/0013/2012

of 24 January 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral for treprostinil (diethanolamine) (EMEA-001165-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0013/2012

of 24 January 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral for treprostinil (diethanolamine) (EMA-001165-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by United Therapeutics Europe Ltd on 10 February 2011 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 December 2011, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for treprostinil (diethanolamine), prolonged-release tablet, prolonged-release oral liquid formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for treprostinil (diethanolamine), prolonged-release tablet, prolonged-release oral liquid formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to United Therapeutics Europe Ltd, Unither House, Curfew Bell Road, Chertsey, Surrey, KT16 9FG, United Kingdom.

Done at London, 24 January 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/13957/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-001165-PIP01-11

Scope of the application

Active substance(s):

Treprostinil (diethanolamine)

Condition(s):

Treatment of pulmonary hypertension

Pharmaceutical form(s):

Prolonged-release tablet

Prolonged-release oral liquid formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

United Therapeutics Europe Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, United Therapeutics Europe Ltd submitted for agreement to the European Medicines Agency on 10 February 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 23 March 2011.

Supplementary information was provided by the applicant on 19 September 2011. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a waiver.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 9 December 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of pulmonary hypertension

2.1.1. Indication(s) targeted by the PIP

Treatment of primary pulmonary arterial hypertension (PAH)

Treatment of persistent pulmonary hypertension of the newborn (PPHN)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Prolonged-release tablet

Prolonged-release oral liquid formulation

2.1.4. Studies

Area	Number of studies	Description
Quality	2	Study 1 Development of an age-appropriate prolonged-release oral liquid formulation. Study 2: Study of nasogastric tube administration of the prolonged-release oral liquid formulation in vitro.
Non-clinical	0	Not applicable.
Clinical	5	Study 3 Open-label, multiple dose uncontrolled study to evaluate safety, tolerability and pharmacokinetics of treprostinil diethanolamine prolonged-release tablet in children from 8 to less than 18 years of age with pulmonary arterial hypertension. Study 4 Open-label, single dose, fasted and fed state crossover trial to evaluate pharmacokinetics, safety and tolerability of treprostinil diethanolamine oral liquid formulation in healthy adults.

Area	Number of studies	Description
		Study 5 Open-label, single dose trial to evaluate pharmacokinetics, safety and tolerability of treprostinil diethanolamine oral liquid formulation in children from birth to less than 8 years of age with pulmonary arterial hypertension. Study 6 Double blind, randomised, multiple dose placebo controlled (add on to baseline therapy) trial to evaluate efficacy and safety of treprostinil diethanolamine oral liquid formulation in children from birth to less than 8 years of age with pulmonary arterial hypertension. Study 7 Efficacy bridging and interpolation study covering children with pulmonary arterial hypertension from 8 to less than 18 years of age.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By December 2025.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.